Navigation Links
Adynxx Initiates Phase 2 Dose-Ranging Study of AYX1, Lead Compound for the Prevention of Post-Surgical Pain
Date:7/16/2014

SAN FRANCISCO, July 16, 2014 /PRNewswire/ -- Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. With ADYX-003, Adynxx will build on the results of the recently completed ADYX-002 Phase 2 proof-of-concept study.

The 120-patient, placebo-controlled study will evaluate the safety and efficacy of two dose-volume levels of a single administration of AYX1 given prior to unilateral total knee replacement to reduce acute pain with movement and to prevent the transition to persistent pain. The study will follow patients for 42 days with a primary endpoint of pain with walking. Secondary endpoints include pain at rest, pain with knee range of motion, opioid consumption and extent of functional recovery. Further details of the study can be found at www.clinicaltrials.gov.

"In the ADYX-002 proof-of-concept study, AYX1 was well-tolerated and demonstrated a consistent treatment effect across a spectrum of pre-defined movement-evoked pain and range-of-motion assessments. Further, this first efficacy study was very informative regarding the dose-volume relationship that drives the AYX1 treatment effect at its site of action," said Donald Manning, M.D., Ph.D., chief medical officer of Adynxx. "The current ADYX-003 study is designed to leverage these first Phase 2 data to further enhance the scope and magnitude of the AYX1 therapeutic effect." 

"The clinical results to date support Adynxx's approach to the treatment of pain and we are committed to advancing the development of AYX1 as rapidly as possible," added Julien Mamet, Ph.D., founder and chief scientific office
'/>"/>

SOURCE Adynxx
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1
2. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
3. Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
4. Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
5. Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation
6. MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
7. Tandem Diabetes Care Initiates Voluntary Recall for Specific Lots of Insulin Cartridges Used with t:slim Insulin Pump
8. Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine
9. Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
10. Cameron Associates Initiates Coverage of Brainsway, Ltd.
11. Heptares Initiates Clinical Study With First Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... International Inc. (NYSE: MTD ) today announced second ... , Sales in local currency increased 3% ... sales decreased 4% as currency reduced sales growth by ... diluted share as reported (EPS) were $2.73, compared with ... , an increase of 9% over the prior-year ...
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... AXA Research Fund closed out its first year of existence. ... 13 million to various European research institutions.The purpose of the ... risks in the world by supporting cutting edge scientific research. ... million over five years, making it a major initiative in ...
... N.J., March 23 Each year in the United States ... myeloma. These new cases account for 10 percent of ... For several types of leukemia, the survival rate has ... James M. Golubieski, president of Foundation Venture Capital Group, LLC, ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:7/31/2015)... ... ... Like nearly every other form of surgery, it shouldn't come as a ... less intrusive and painful. Leading these advances in the United States has been ... as the only doctor in the United States who is qualified to practice, and ...
(Date:7/31/2015)... ... ... The Heart Fit Clinic has increased a patient's fitness level 60 percent ... beats versus 100 beats, this is a big deal," says Diamond Fernandes, director of ... patients with heart disease," he adds. People with angina are able to do a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby sports physiotherapy clinic, Absolute ... understanding and treatment of ankle sprains. A common sports injury, ankle sprains are ... dangerous if the condition augments and causes more disruption. Absolute PhysioCare’s blog discusses ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 ... announce that they are the latest recipients of the Center of Clinical Excellence ... of the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair ...
(Date:7/31/2015)... ... ... is a reputable source of authentic USA vs. Australia tickets at Ford Field ... Team in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup ... was awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
Breaking Medicine News(10 mins):Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2
... Health Care for All Depends on Adequate RN StaffingSILVER SPRING, ... American Nurses, AFL-CIO, pledged to redouble their efforts to secure ... Schakowsky (D-IL) -- that would make federal RN staffing ratios ... Nurses Week, I can think of no better gift for ...
... at American College of Obstetricians and Gynecologists, 57th Annual ... Surgical, Inc., a medical device company that has developed ... technology, released results from a preclinical study demonstrating that ... improved fascia incision healing in an in vivo model ...
... 2009 In a letter to the Editor of the ... by Elsevier, S. Lefebvre and J.S. Weese from the University ... MRSA and C.difficile could be passed between pet ... C. difficile may have been transferred to the ...
... blood clots are often recommended to stop these medications ... However, interruption of these medications can place patients at ... by Shai Friedland at the VA Palo Alto hospital ... without interrupting anticoagulation. Their study will be published on ...
... Elsevier, the world,s leading publisher of scientific, technical, ... Walsh, MSc, FACP, FRCP (Edin) on receiving the ... Project on Death in America (PDIA) Palliative Medicine ... AAHPM 2009 Annual Assembly on March 26. , ...
... Work, Money and the EconomySeven out of 10 ... 7 Economic pressures are having an increasing ... to a new survey by the American Psychological ... reporting significant stress related to work, money, housing ...
Cached Medicine News:Health News:UAN Hails Reintroduction of Federal RN Staffing Ratio Bill and Vows to Work for Passage 2Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 2Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 3Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 4Health News:PEAK Surgical Announces Positive Fascia Incision Healing Results From Preclinical Study of PEAK PlasmaBlade(TM) for Gynecologic Surgery 5Health News:Transmission of MRSA and Clostridium difficile through dogs 2Health News:Author Declan Walsh honored with National Leadership Award in Palliative Medicine 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 2Health News:APA Poll Finds Economic Stress Taking a Toll on Men 3
... Size: 3.0 x 7.5 x ... Scleral Sponge II line designed by ... material is a closed cell sponge ... are soft with rounded edges to ...
... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... mm. Half oval. The original Scleral Sponge II ... been modified by Dr. Joseph Olk with this ... cell sponge which is non-toxic and non-antigenic. Implants ... intrusion. These implants are packaged sterile and sold ...
Medicine Products: